Today on Drug Discovery & Development
Agentic AI-powered literature reviews: Reduce research burdens and accelerate insights
Literature reviews play an essential role in drug development. Searching, screening and drawing insights from vast volumes of research provides a necessary evidence base for clinical decisions and regulatory submissions, yet the thoroughness that makes these reviews so valuable also makes them resource intensive. Conducting literature reviews requires meticulous planning, deep domain expertise, significant manual…
The ‘forever drug’ assumption about GLP-1s may be wrong, according to nference analysis
Last month, a University of Oxford meta-analysis published in The BMJ examining 37 studies with over 9,000 participants found that patients who stopped taking GLP-1s were likely to gain approximately 1 pound per month, returning to their previous weight within two years. However, data shared with Reuters ahead of peer review shows this may not…
Drug Discovery and Development See More >
Pharma 2035 Playbook: Speed, focus and conviction in an uncertain world
The pharmaceutical industry is inherently uncertain, driven by high dispersion in the value realized by successful bets in comparison to those that fail. Speaking in the language of finance, operating a business in pharmaceutical industry is akin to investing in microcaps, where one invests in assets based on ultra long-term growth outlook, strong competitive positioning…
Sponsored Content See More >
How Endogenous Tagging is Reshaping Protein AnalysisUnderstanding how proteins behave inside living cells is essential for modern drug discovery. Yet many widely used approaches, particularly plasmid…
Advancing Pressure Protection in Biopharma: How Integrated Bypass Technology Elevates Single-Use Pump Designby Michael Irving, Xylem In pharmaceutical and biopharmaceutical manufacturing, there is zero margin for error when it comes to process…
What sets oncology biosimilars apart: Anticipating key challenges in the development landscapeBy Kimberly Salgado, ICON plc Advancements in biologic therapies have greatly improved our ability to treat cancer over the last…
Complexity’s counterpoint: Understanding protocol optimization In recent years, the clinical research landscape has been marked by a steady rise in protocol complexity with more endpoints…
Optimizing Data Pipelines in Life Sciences with AI-Driven Integration and FHIRSponsored by Infor. Data management in life sciences is inherently complex. Data is fragmented across multiple systems — such…
Accelerating life sciences with AI This case study is sponsored by Infor. Artificial intelligence can revolutionize clinical interoperability by building bridges across data silos. Machine…
Advancing Clinical Trials and ResearchThis case study is sponsored by Infor. In the complex landscape of clinical trials and medical research, data fragmentation remains…
Multidisciplinary approaches optimize contract drug discovery
5 Key Questions in Conducting Global Usability StudiesBy Dr Bryce G Rutter, Head Noble Consulting Services Evaluating device usability throughout the product development process is crucial. A…
Leveraging HF/UX/ID Services to Optimize the Design of Combination Devices for Arthritic HandsBy Dr. Bryce G Rutter, Head of Consulting Services Arthritis changes how people grasp and manipulate an object, reducing the…
Ask the Expert: Navigating the New FDA Rules on Laboratory Developed Tests (LDTs)The U.S. FDA released a final rule to regulate laboratory developed tests (LDTs) on May 6, 2024, making it clear…
How tailored qPCR assays can unlock microbiome and precision medicine potential Sponsored by Diversigen, Inc. Quantitative Polymerase Chain Reaction (qPCR) — also known as real-time PCR — is a molecular…
Genomics/Proteomics See More >
Columbia-CZ team develops 10.3M parameter model that outperforms 100M parameter rivals on cell type classification
A new foundation model called GREmLN from a Columbia and Chan Zuckerberg Biohub team, delivers superior cell-type classification with only 10.3 million parameters, outpacing rivals like the 100-million-parameter scFoundation. Released July 9 on bioRxiv, it taps gene regulatory networks to achieve a 0.929 macro F1 score on immune cell data. “Instead of using large language…
Spatial biology: Transforming our understanding of cellular environments
Biotech in 2025: Precision medicine, smarter investments, and more emphasis on RWD in clinical trials
Genomics in 2025: How $500 whole genome sequencing could democratize genomic data
St. Jude pioneers gene editing and structural biology to advance pediatric research
Infectious Disease See More >
Vaccines, autism and America: A stress test for public health standards
Vaccines, autism and America: A stress test for public health standards The CDC recently overhauled its “Autism and Vaccines” webpage, telling readers that the familiar claim that “vaccines do not cause autism” is not evidence based because studies have not ruled out the possible effect from infant vaccines. It goes on to note that “correlation…
Oncology See More >
S&P report highlights Big Pharma’s concentration risk amid pre-JPM deal flurry
Merck is an A+ credit, a global oncology powerhouse, and still, about half its 2024 pharma revenue came from a single product: Keytruda, a product whose loss of exclusivity will hit around 2028 in the U.S. S&P Global Ratings calls that kind of concentration a “material weakness.” Merck isn’t alone. A new S&P analysis of…
